Regulation of human CycLT2-like GPCR protein
AssigneeBayer Aktiengesellschaft
InventorYonghong Xiao
Life of this patent
Estimating the term…
Abstract
Reagents which regulate human CysLT2-like GPCR protein and reagents which bind to human CysLT2-like GPCR gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to peripheral and central nervous system disease, asthma and cardiovascular disease.
Claims20
A cDNA encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 2.
An expression vector comprising a polynucleotide which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 2.
A host cell comprising an expression vector which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 2.
A purified polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 2.
A fusion protein comprising a polypeptide having the amino acid sequence shown in SEQ ID NO:
- 2.
A method of producing a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 2, comprising the steps of:
- culturing a host cell comprising an expression vector which encodes the polypeptide under conditions whereby the polypeptide is expressed;
- and
- isolating the polypeptide.
A method of detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 2, comprising the steps of:
- hybridizing a polynucleotide comprising 11 contiguous nucleotides of SEQ ID NO:
- 1 to nucleic acid material of a biological sample, thereby forming a hybridization complex;
- and
- detecting the hybridization complex.
A method of detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 2, comprising the steps of:
- contacting a biological sample with a reagent that specifically binds to the polypeptide to form a reagent-polypeptide complex;
- and
- detecting the reagent-polypeptide complex.
A method of screening for agents which can regulate the activity of a cysteinyl leukotriene-like GPCR, comprising the steps of:
- contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of:
- (1) amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO:
- 2 and (2) the amino acid sequence shown in SEQ ID NO:
- 2;
- and
- detecting binding of the test compound to the polypeptide, wherein a test compound which binds to the polypeptide is identified as a potential agent for regulating activity of the cysteinyl leukotriene-like GPCR.
A method of screening for agents which regulate an activity of a human cysteinyl leukotriene-like GPCR, comprising the steps of:
- contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of:
- (1) amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO:
- 2 and (2) the amino acid sequence shown in SEQ ID NO:
- 2;
- and
- detecting an activity of the polypeptide, wherein a test compound which increases the activity of the polypeptide is identified as a potential agent for increasing the activity of the human cysteinyl leukotriene-like GPCR, and wherein a test compound which decreases the activity of the polypeptide is identified as a potential agent for decreasing the activity of the human cysteinyl leukotriene-like GPCR.
A method of screening for agents which regulate an activity of a human cysteinyl leukotriene-like GPCR, comprising the steps of:
- contacting a test compound with a product encoded by a polynucleotide which comprises the nucleotide sequence shown in SEQ ID NO:
- 1;
- and
- detecting binding of the test compound to the product, wherein a test compound which binds to the product is identified as a potential agent for regulating the activity of the human cysteinyl leukotriene-like GPCR.
A method of reducing activity of a human cysteinyl leukotriene-like GPCR, comprising the step of:
- contacting a cell with a reagent which specifically binds to a product encoded by a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO:
- 1, whereby the activity of a human cysteinyl leukotriene-like GPCR is reduced.
A pharmaceutical composition, comprising:
- a reagent which specifically binds to a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 2;
- and
- a pharmaceutically acceptable carrier.
A pharmaceutical composition, comprising:
- a reagent which specifically binds to a product of a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO:
- 1;
- and
- a pharmaceutically acceptable carrier.
A pharmaceutical composition, comprising:
- an expression vector encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO:
- 2;
- and
- a pharmaceutically acceptable carrier.
A method of treating asthma, comprising the step of:
- administering to a patient in need thereof a therapeutically effective dose of a reagent that inhibits a function of a human cysteinyl leukotriene-like GPCR comprising the amino acid sequence shown in SEQ ID NO:
- 2, whereby symptoms of the asthma are ameliorated.
A method of treating a central nervous system disorder, comprising the step of:
- administering to a patient in need thereof a therapeutically effective dose of a reagent that inhibits a function of a human cysteinyl leukotriene-like GPCR comprising the amino acid sequence shown in SEQ ID NO:
- 2, whereby symptoms of the central nervous system disorder are ameliorated.
A method of treating myocardial infarction, comprising the step of:
- orally administering to a patient in need thereof a therapeutically effective dose of an antagonist of a human cysteinyl leukotriene-like GPCR comprising the amino acid sequence shown in SEQ ID NO:
- 2, whereby symptoms of the myocardial infarction are ameliorated.
Dependencies are inferred from the claim text.